Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 29 strange trades.

Benzinga

AbbVie Whale Trades For June 14

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial

AbbVie Inc (NYSE:ABBV) announced primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE NHL-1 phase 2 trial of epcoritamab. Epcoritamab demonstrated efficacy with durable responses in patients who had previously received at least two prior lines of anti-lymphoma therapy. The study cohort, which included 157 relapsed/refractory LBCL patients, demonstrated…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.42% on an annualized basis producing an average annual return of 16.4%. Currently, AbbVie has a market capitalization of $263.04 billion.

Benzinga

You no longer need surgery to be diagnosed with endometriosis. Here's what's changed

By age 44, endometriosis affects around one in nine women and people assigned female at birth in Australia.

The Conversation

AbbVie Whale Trades For June 01

A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades.

Benzinga

Supreme Court leak prompts investors to press companies on abortion

WASHINGTON — Activist shareholders, seeking to galvanize support following a leaked Supreme Court draft opinion indicating that justices are poised to overturn Roe v. Wade, are pressing companies to explicitly explain how they will support their workers’ access to abortion and reproductive health services.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

SCOTUS leak prompts investors to press companies on abortion - Roll Call

Activist shareholders are pressuring companies on access to abortion after a leaked draft Supreme Court opinion.

Roll Call

If You Invested $1000 In AbbVie 5 Years Ago, Here's How Much You Would Have Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 7.1% on an annualized basis producing an average annual return of 17.45%. Currently, AbbVie has a market capitalization of $260.97 billion.

Benzinga

What 8 Analyst Ratings Have To Say About AbbVie

Within the last quarter, AbbVie (NYSE:ABBV) has observed the following analyst ratings:

Benzinga

AbbVie Submits FDA Application For Continuous, 24-Hour Infusion Therapy For Parkinson's

AbbVie Inc (NYSE:ABBV) submitted its FDA marketing application for ABBV-951, a solution of levodopa and carbidopa prodrugs being evaluated in advanced Parkinson’s patients who don’t respond well to oral therapy. AbbVie’s theory here revolves around using a continuous, 24-hour infusion of its therapy. The levodopa and carbidopa prodrugs are delivered in small doses…

Benzinga

AbbVie Whale Trades Spotted

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

AbbVie, Cugene Ink Licensing Pact For Autoimmune & Inflammatory Disease Candidate

AbbVie Inc (ABBV) and Cugene Inc have announced an exclusive worldwide license option agreement for CUG252 for the potential treatment of autoimmune and inflammatory diseases. Cugene's lead candidate, CUG252, is an engineered IL-2 mutein designed to selectively activate and expand immune-suppressive Treg cells while reducing undesired IL-2 activity on other IL-2 receptor-expressing cells for autoimmune…

Benzinga

AbbVie's Upadacitinib Shows Clinical Response In Crohn's Disease Maintenance Study At One Year

AbbVie Inc (NYSE:ABBV) announced topline results from U-ENDURE Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease. The trial included patients who had an inadequate response or were intolerant to conventional or biologic therapy. A significantly higher proportion of patients who received upadacitinib 15 mg or 30…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Looking At AbbVie's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades.

Benzinga

U.S. FDA Approves AbbVie's RINVOQ® (upadacitinib) for Ankylosing Spondylitis (AS)

The U.S. Food and Drug Administration (FDA) has approved AbbVie’s (NYSE: ABBV) RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) .

Benzinga

AbbVie Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 30 strange trades.

Benzinga

AbbVie Shares Fall On Mixed Bag Q1 Results, Cuts FY22 Profit Guidance

AbbVie Inc (NYSE:ABBV) reports Q1 adjusted EPS of $3.16, higher than the $2.89 reported a year ago and beating the consensus of $3.14. Overall sales increased 4.1% Y/Y (5.4% on an operational basis) to $13.54 billion, missing the consensus of $13.63 billion. The immunology portfolio generated $6.14 billion in sales, +6.9% (+8.1%…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

AbbVie: Q1 Earnings Insights

AbbVie (NYSE:ABBV) reported its Q1 earnings results on Friday, April 29, 2022 at 07:44 AM. Here's what investors need to know about the announcement.

Benzinga

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 6.18% on an annualized basis producing an average annual return of 18.59%. Currently, AbbVie has a market capitalization of $275.98 billion.

Benzinga

Preview: AbbVie's Earnings

AbbVie (NYSE:ABBV) is set to give its latest quarterly earnings report on Friday, 2022-04-29. Here's what investors need to know before the announcement. Analysts estimate that AbbVie will report an earnings per share (EPS) of $3.14.

Benzinga

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Analyst Ratings for AbbVie

Analysts have provided the following ratings for AbbVie (NYSE:ABBV) within the last quarter:

Benzinga

AbbVie Walks Away From Parkinson's Drug Pact With BioArctic

AbbVie Inc (NYSE:ABBV) has ended a research partnership with Sweden's BioArctic, backing out further development of an experimental Parkinson's disease drug and other related medicines. A clinicaltrials.gov listing for ABBV-0805 says a Phase I study is "Withdrawn (Strategic considerations)." The partnership between AbbVie and BioArctic, which began in 2016, was focused on antibody drugs…

Benzinga

AbbVie Whale Trades For April 19

1 … 7 8 9 10

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.